2. Signaling Pathways
  3. Immunology/Inflammation
  4. PD-1/PD-L1

PD-1/PD-L1

PD-1/Programmed death-ligand 1

PD-1/PD-L1

Related Products

PDF 0.7 MB

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.

PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99145A
    Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1)
    		Inhibitor
    Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse PD-L1/B7-H1.
    Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1)
  • HY-P990623
    MDX-1105
    		Inhibitor ≥99.0%
    MDX-1105 is a human antibody expressed in CHO that targets B7-H1/PD-L1/CD274. MDX-1105 has a huIgG4SP type heavy chain, and its predicted molecular weight (MW) is 150 kDa. The isotype control for MDX-1105 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    MDX-1105
  • HY-101098
    PD-1-IN-18
    		Inhibitor
    PD-1-IN-18 is a PD1 signaling pathway inhibitor, which acts as an immunomodulator.
    PD-1-IN-18
  • HY-101097A
    PD-1-IN-17 TFA
    		Inhibitor
    PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM.
    PD-1-IN-17 TFA
  • HY-103048
    PD-1/PD-L1-IN 3
    		Inhibitor
    PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases.
    PD-1/PD-L1-IN 3
  • HY-100022A
    Tomivosertib hydrochloride
    		Inhibitor
    Tomivosertib hydrochlorideis a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib hydrochloride treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines. Tomivosertib hydrochloride also dramatically downregulates PD-L1 protein abundance.
    Tomivosertib hydrochloride
  • HY-101093B
    PD-1-IN-20
    		Inhibitor
    PD-1-IN-20 is the less active enantiomer of PD-1-IN-1. PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4.
    PD-1-IN-20
  • HY-P99633
    Garivulimab
    		Inhibitor
    Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity.
    Garivulimab
  • HY-P99943
    Erfonrilimab
    		99.98%
    Erfonrilimab (KN-046) is an anti-PDL1/CTLA-4 monoclonal antibody.
    Erfonrilimab
  • HY-P99499
    Cetrelimab
    		Inhibitor ≥99.0%
    Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo.
    Cetrelimab
  • HY-P99799
    Pacmilimab
    		Inhibitor
    Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity.
    Pacmilimab
  • HY-P99887
    Pimivalimab
    		Inhibitor
    Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor.
    Pimivalimab
  • HY-P99106
    Acrixolimab
    		Inhibitor
    Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1.
    Acrixolimab
  • HY-P99914
    Emfizatamab
    Emfizatamab is an anti-CD19/CD3E/TNFRSF9/PD-L1 monoclonal antibody.
    Emfizatamab
  • HY-B0008A
    Sulindac sodium
    		Modulator
    Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer.
    Sulindac sodium
  • HY-P990074
    Enlonstobart
    		Inhibitor
    Enlonstobart is a human immunoglobulin G4-kappa, anti-PDCD1 monoclonal antibody. Enlonstobart is an immunostimulant and antineoplastic.
    Enlonstobart
  • HY-P990757
    Ragistomig
    Ragistomig is an anti-TNFRSF9/CD274 IgG1 monoclonal antibody composed of a κ light chain and a variable region with a λ light chain and an IgG1 heavy chain. The overall structure is a dimer composed of two identical IgG1 heavy chains.
    Ragistomig
  • HY-129172A
    PD-1/PD-L1-IN 5
    		Inhibitor
    PD-1/PD-L1-IN 5 is a PD-1/PD-L1 protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC50 of ≤100 nM.
    PD-1/PD-L1-IN 5
  • HY-P99698
    Lesabelimab
    		Inhibitor
    Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor.
    Lesabelimab
  • HY-P990077
    Pidilizumab
    		Inhibitor
    Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research.
    Pidilizumab
Cat. No. Product Name / Synonyms Application Reactivity